ENTX logo

ENTERA BIO LTD

ENTXNASDAQ
🏆 #3026 by market capEarnings Nov 12US Equity
$453.41▼ $33.92 (−7.48%)
Simulated price
🔔
Track ENTX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 7.5%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$468M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
4.0%
Thin
💵FCF Margin
—
⚖️P/S Ratio
2096.9x
Expensive
Otter Score
68
Fair
No chart data available for ENTX.

Trading Snapshot

Day Range
$449.89 – $460.09
52-Week Range
$0.91 – $4.20
Volume
$2.91B
Avg Volume
$2.62B
Shares Outstanding
172.3M
Next Earnings
Nov 4, 2026

Fundamentals Snapshot

Annual Revenue
$223,000
Last Q Revenue
$58,502
P/E Ratio
—
P/S Ratio
2096.9x
EPS (TTM)
$-0.35
Dividend Yield
—
Dilution (1yr)
+22.7%

Why Investors Own ENTX

  • ✓High-growth profile — revenue up +39.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 51% gross margin and 29% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ENTX logo

ENTERA BIO LTD

ENTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$42K▼ −76.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
0.0%▼ −100.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$12M▲ +20.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$7M▲ +9.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
46.2M▲ +22.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7M▼ −$2M YoY
StockOtter · stockotter.space

About ENTERA BIO LTD

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$563.12
▲ +24.2% Upside
High Target$615.57
Low Target$480.14
Based on 30 analysts

Latest News & Updates

🚀
Barron’s·2h ago

ENTERA BIO LTD tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift ENTX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

ENTERA BIO LTD announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.